Lexeo Therapeutics
Rare Disease Therapeutics
5open roles
$150kmedian advertised pay
$2.9Mraised in 6 rounds
Atruth index, 87 of 100
Overview
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated.
How Lexeo Therapeutics hires
Truth index
A 87/100
Median time to fill
85 days
Ghost roles
0%
Stale roles
33%
Reposted roles
0%
Lexeo Therapeutics scores A on the Alion truth index (A is best, E worst), measured over 3 open roles re-checked against its own hiring board: 0% look like ghost listings, 33% have gone stale and 0% are the same role posted again. Its roles close in a median of 85 days. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed
Jobs
$111k – $150k per year · In office · Full-Time · 5+ years exp · PhD · New York
Next-Generation Sequencing
Mass Spectrometry
HPLC
Chromatography
Apply
$111k – $150k per year · In office · Full-Time · 5+ years exp · PhD · New York
qPCR
ELISA
Mass Spectrometry
Immunohistochemistry
GraphPad Prism
Apply
$127k – $150k per year · In office · Full-Time · 1+ year exp · PhD · New York
Cell Culture
Apply
$93k – $154k per year · Hybrid · Full-Time · 8+ years exp · Bachelor's Degree · New York
ELISA
GMP
Apply
$100k – $139k per year · In office · Full-Time · 6+ years exp · PhD · New York
qPCR
Cell Culture
GMP
Benchling
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$150k
Typical range
$139k – $230k
Open positions
6
6
Jobs
Middle
66.7%
Senior
16.7%
Architect
16.7%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Middle | 4 | $150k | $139k – $150k |
| Senior | 1 | $154k | $154k |
| Architect | 1 | $230k | $230k |
Highest paying role
Associate Director, Marketing
$230k
Normalized to USD per year
All salaries at Lexeo Therapeutics
By role, level and city, against the market · 6 jobs with pay
Visa sponsorship
1
H-1B filings in 12 months
$183k
Median offered salary
7
Open roles in United States
Who they sponsor
Natural sciences managers
1
In the register as Lexeo Therapeutics, Inc., New York, NY
Other sponsors in the same field
Vertex Pharmaceuticals 174 filings
Sanofi 62 filings
Alnylam 36 filings
Neurocrine Biosciences 18 filings
See 7 open roles Alert me
US Department of Labor · latest filing Feb 6, 2026 · Visa details by country
Growth
Hiring Momentum
46/100
Stable
Open positions
7
2 opened / 1 closed in 30 days
Median time-to-fill
86 days
faster than 14% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
50% ▼
Science & Research
38% ▲
Marketing
13% ▲
Activity Timeline
Added Immunohistochemistry to stack
Oct 2026
Added GraphPad Prism to stack
Oct 2026
Added Next-Generation Sequencing to stack
Oct 2026
Added Mass Spectrometry to stack
Oct 2026
Added HPLC to stack
Oct 2026
Added Chromatography to stack
Oct 2026
Added Cell Culture to stack
Oct 2026
Added Benchling to stack
Oct 2026
Added GMP to stack
Oct 2026
Added Western Blot to stack
Oct 2026
Added qPCR to stack
Oct 2026
Added PCR to stack
Oct 2026
Tech stack
Technologies named in job postings at Lexeo Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
19
Postings analysed
9
Stack modernity
58/100
Frameworks & libraries
XGBoost
Sign in to see how your skills match this stack
Sign In
Full Lexeo Therapeutics tech stack
19 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Longitude CapitalVia a fund
78 portfolio companies: Zenas BioPharma, Mobia Medical, Inc. and 76 more
Omega FundsVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Lexeo Therapeutics advances gene therapy and gains RMAT status
Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.
Read more
Report
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
Detailed price information for Lexeo Therapeutics Inc (LXEO-Q) from The Globe and Mail including charting and trades.
Read more
Report
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a consensus buy from all eleven analysts covering the stock. While the target price ranges from $1
Read more
Report
Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials
Read more
Report
Lexeo Therapeutics price target lowered to $19 from $20 at Leerink
Leerink lowered the firm's price target on Lexeo Therapeutics (LXEO) to $19 from $20 and keeps an Outperform rating on the shares. The firm notes Lexeo announced Q3 financial results and alignment with FDA on a registrational path for LX2006 in Friedreich
Read more
Report
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
--Lexeo Therapeutics, Inc., a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer' s disease, today announced that the company will conduct an investor w
Read more
Report
Human Gene Therapy
Positron emission tomography (PET) images 24 hr after administration of I-124 labeled AAVrh10 by the intracisternal route to a nonhuman primate, showing differences in organ biodistribution between serotype naïve (left) and serotype immune (right) status.
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
New York
New York
United States
HQ
345 Park Avenue South, 6th Floor,
7 open roles 8 posted in 90 days 14% engineering 50-200 est. staff $162k Avg Salary
hires for Biotech, Marketing, Operations